HR
VRTX icon

Hayden Royal’s Vertex Pharmaceuticals VRTX Stock Holding History

Hayden Royal’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$233K Sell
1,060
-121
-10% -$23.5K 0.55% 65
2021
Q3 		$214K Buy
1,181
+158
+15% +$30.8K 0.35% 79
2021
Q2 		$206K Buy
1,023
+31
+3% +$6.48K 0.11% 186
2021
Q1 		$213K Buy
+992
New +$218K 0.12% 176
2020
Q3 		– Sell
-4,879
Closed -$1.42M – 233
2020
Q2 		$1.42M Buy
+4,879
New +$1.32M 0.8% 27

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Hayden Royal's VRTX Position: Q4 2021 in Review

Hayden Royal reduced its Vertex Pharmaceuticals (VRTX) stake by 10% in Q4 2021, selling an estimated $23.5K and leaving 1,060 shares worth $233K. The position accounts for 0.55% of the portfolio, ranked #65.

Hayden Royal first reported a position in VRTX in Q2 2020 and has held it in 5 quarters since. The position peaked at $1.42M in Q2 2020. 1,033 funds tracked by Wall St. Rank hold VRTX as of Q4 2021.

  • Hayden Royal held 1,060 shares of Vertex Pharmaceuticals worth $233K as of Q4 2021.
  • Hayden Royal sold 121 Vertex Pharmaceuticals shares in Q4 2021, an estimated $23.5K.
  • Vertex Pharmaceuticals made up 0.55% of Hayden Royal's portfolio in Q4 2021, its #65 holding.
  • Hayden Royal first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 5 quarters since.
  • Hayden Royal's Vertex Pharmaceuticals position peaked at $1.42M in Q2 2020.
  • 1,033 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2021.

Based on Hayden Royal's 13F filing for Q4 2021, filed 7 Feb 2022.